SEARCH RESULT

Total Matching Records found : 326

Supreme Court refuses to hear challenge on NPPA decision -Apoorva

-Livemint The petition challenged NPPA's decision of withdrawing its internal guideline to set prices of non-essential drugs New Delhi: The Supreme Court on Monday refused to entertain a petition challenging a decision by the country's drug price regulator to withdraw its internal guideline to set prices of non-essential drugs. Earlier this year, the National Pharmaceutical Pricing Authority (NPPA) issued a guideline empowering itself to cap the prices of 108 non-essential drugs, attracting...

More »

Reforming the health care sector -Ian D Spatz

-The Hindu Obamacare and other such examples make a compelling case for seeking the right combination of roles for the public and private sector in health reform in India Nail or screw? Which is best to join pieces of wood? In carpentry, the answer is that each offers benefits depending on the application. With health care reform, the choice of public or private sector financing, delivery and regulation is subject to a...

More »

Pvt sector deserts war on TB, funding down 33% since 2011 -Subodh Varma

-The Times of India Even as tuberculosis (TB) continues to haunt the world, a new study has revealed that funding for research and development of new drugs to fight the disease is floundering. Private sector funding has declined by more than a third since 2011 as pharma companies are closing their TB research programmes. Pfizer shut down its TB drug discovery programme in 2012, AstraZeneca in 2013 and Novartis in 2014. Meanwhile,...

More »

Subramanian till recently had opposed India on IPR

-The Times of India The man who has been appointed the chief economic advisor to the government of India, Arvind Subramanian, was until recently urging the US to initiate disputes against India before the World Trade Organisation and also seeking changes in provisions within Indian patent law aimed at preventing frivolous patenting and preventing pharma companies from getting extensions on patents by tweaking existing drugs and passing them off as innovations. Subramanian...

More »

Mala Fide Decision on Drug Prices

-Economic and Political Weekly   The decision to reduce the powers of the drug pricing body goes against the interest of public health. The decision of the Government of India to withdraw the power of the National Pharmaceutical Pricing Authority (NPPA) to set price controls on drugs that are not on the National List of Essential Medicines (NLEM) raises questions on the Narendra Modi regime's commitment to people's welfare. One must ask if...

More »

Video Archives

Archives

share on Facebook
Twitter
RSS
Feedback
Read Later

Contact Form

Please enter security code
      Close